Economic value of vaccinating geographically hard-to-reach populations with measles vaccine: A modeling application in Kenya

Vaccine. 2019 Apr 17;37(17):2377-2386. doi: 10.1016/j.vaccine.2019.03.007. Epub 2019 Mar 25.

Abstract

Background: Since special efforts are necessary to vaccinate people living far from fixed vaccination posts, decision makers are interested in knowing the economic value of such efforts.

Methods: Using our immunization geospatial information system platform and a measles compartment model, we quantified the health and economic value of a 2-dose measles immunization outreach strategy for children <24 months of age in Kenya who are geographically hard-to-reach (i.e., those living outside a specified catchment radius from fixed vaccination posts, which served as a proxy for access to services).

Findings: When geographically hard-to-reach children were not vaccinated, there were 1427 total measles cases from 2016 to 2020, resulting in $9.5 million ($3.1-$18.1 million) in direct medical costs and productivity losses and 7504 (3338-12,903) disability-adjusted life years (DALYs). The outreach strategy cost $76 ($23-$142)/DALY averted (compared to no outreach) when 25% of geographically hard-to-reach children received MCV1, $122 ($40-$226)/DALY averted when 50% received MCV1, and $274 ($123-$478)/DALY averted when 100% received MCV1.

Conclusion: Outreach vaccination among geographically hard-to-reach populations was highly cost-effective in a wide variety of scenarios, offering support for investment in an effective outreach vaccination strategy.

Keywords: Economic; Hard-to-reach populations; Vaccination.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Cost-Benefit Analysis*
  • Geography, Medical
  • Humans
  • Kenya / epidemiology
  • Measles / epidemiology*
  • Measles / prevention & control*
  • Measles Vaccine / administration & dosage
  • Measles Vaccine / economics*
  • Measles Vaccine / immunology
  • Models, Theoretical
  • Population Surveillance
  • Risk Factors*
  • Vaccination / economics
  • Vaccination / methods

Substances

  • Measles Vaccine